Age-standardized prevalence rates of gynecological diseases across 21 GBD regions, by SDI, from 1990 to 2021. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage changes in the prevalence rate of specific gynecological diseases from 1990 to 2021, categorized by age group and SDI. by Xiaofeng He (2618752)

Subjects:

Prevalence of gynecological diseases (GDs) among women of childbearing age in 2021, along with their changes from 1990 to 2021, and the contribution of each GD to the overall preva... by Xiaofeng He (2618752)

Subjects:

The changing trends of the main differential metabolites in the WKY, SHR and Model groups. by Xiao Zhang (152326)

Subjects:

Mean percent survival of newly emerged worker bees (n = 180/group) in the laboratory inoculated with 1 × 10⁷ CFU/bee <i>M. plutonius</i> 2019BC1 and/or one (1X) or three... by Midhun Sebastian Jose (19336846)

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

UpSet plot summarising key differentially expressed gene trends and Gene ontology analysis of differentially expressed genes present only in extremely high viral load group. by Vasanthi Avadhanula (259546)

Subjects:

Smoking-Attributable RA Burden from 2000 to 2021: Global Temporal Trends and Regional Differences in Smoking Prevalence and Burden Indicators. by Kaibin Lin (9911049)

Subjects:

Survival in mice with liver metastases after MBC-005 TREATMENT. by Bryan S. Margulies (21492667)

Subjects:

Sound stress exposure prolonged the period of decreased withdrawal threshold after complete Freund’s adjuvant (CFA) injection. by Satoka Kasai (3861115)

“…(B) 50% withdrawal threshold in CFA-treated mice exposed to sound stress. They showed a significant decrease in 50% withdrawal threshold on day 7 after CFA injection, and CFA-treated mice exposed to sound stress showed a significant decrease in 50% withdrawal threshold during days 7–21 after CFA injection (CFA, on day 7, ****<i>P</i> < 0.001 vs day 0, on day 10, ***<i>P</i> < 0.001 vs day0; CFA + stress, day 7, 10, 14, and 21, ****<i>P</i> < 0.0001 vs day 0, Dunnett’s test). …”

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Subjects: